Abstract
Although patient acceptance is important for biosimilar adoption and reducing healthcare costs, many patients perceive biosimilars to be unsafe and have concerns about switching. Studies show that patients’ characteristics influence negative perceptions toward generic drugs, but little research has explored biosimilar acceptance. This study examines which demographic and psychological characteristics are associated with patients’ safety perceptions and concerns about switching to biosimilars. Ninety-six patients taking bio-originators for rheumatic conditions (65% for rheumatoid arthritis) completed the Brief Illness Perceptions Questionnaire, Beliefs about Medicines Questionnaire and Perceived Sensitivity to Medicines Scale. Demographic factors, information seeking, concerns about switching and safety perceptions were also assessed. Pearson’s correlations and hierarchical linear regressions were conducted to explore whether patient characteristics are associated with perceptions of biosimilars. Negative safety perceptions were associated with being female, short-term bio-originator use, illness beliefs, seeking health information online, high perceived sensitivity to medicines and negative beliefs about medicines. Only being female (β = 0.24, P = 0.02) was independently associated. More concerns about switching were associated with being female, illness beliefs, high perceived sensitivity to medicines, information-seeking behaviours and preferring innovator drugs. Seeking health information online (β = 0.20, P = 0.04), preferring innovator drugs (β = 0.29, P = 0.004) and stronger emotional responses (β = 0.26, P = 0.01) were independently associated. Perceived bio-originator effectiveness was inversely associated with preferring biosimilars (rs= – 0.33, P < 0.001). Patients who have stronger emotional responses to their condition, are females, seek health information online and prefer innovator drugs that have more negative perceptions about biosimilars. Experiences with bio-originators influence attitudes towards switching.
Similar content being viewed by others
References
Eleryan MG, Akhiyat S, Rengifo-Pardo M, Ehrlich A (2016) Biosimilars: Potential implications for clinicians. Clin Cosmet Investig Dermatol 9:135–142. https://doi.org/10.2147/CCID.S91691
Escasany AA, Cumplido DR (2015) Biosimilars: Current reality, promising future? Medicina Clínica (English Edition) 145:18–20. https://doi.org/10.1016/j.medcli.2015.03.006
Patel D, Park KT (2017) Path of interchangeability of biosimilars in pediatric inflammatory bowel disease: Quality before cost savings. J Pediatr Gastroenterol Nutr 65:134–136. https://doi.org/10.1097/MPG.0000000000001572
Sullivan E, Piercy J, Waller J, Black CM, Kachroo S (2017) Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany. PLoS One 12:1–14. https://doi.org/10.1371/journal.pone.0175826
Wilkins AR, Venkat MV, Brown AS, Dong JP, Ran NA, Hirsch JS, Close KL (2014) Patient perspectives on biosimilar insulin. J Diabetes Sci Technol 8:23–25. https://doi.org/10.1177/1932296813515132
Attara G, Bressler B, Bailey R, Marshall JK, Panaccione R, Aumais G (2016) Canadian patient and caregiver perspectives on subsequent entry biologics/biosimilars for inflammatory bowel disease. Gastroenterology 150:443–444. https://doi.org/10.1016/s0016-5085(16)31540-2
Ighani A, Wang JY, Manolson MF (2018) An evaluation of psoriasis patient perceptions and understanding of biosimilars: A Canadian survey comparing biologic and nonbiologic users. J Cutan Med Surg 22:365–367. https://doi.org/10.1177/1203475417746337
Rezk MF, Pieper B (2017) Treatment outcomes with biosimilars: Be aware of the nocebo effect. Rheumatol Ther 4:209–218. https://doi.org/10.1007/s40744-017-0085-z
Betegnie A, Gauchet A, Lehmann A, Grange L, Roustit M, Baudrant M, Bedouch P, Allenet B (2016) An assessment of patients’ adherence using a self-report questionnaire. J Rheumatol 43:724–730. https://doi.org/10.3899/jrheum.150414
Figueiras MJ, Alves NC, Marcelino D, Cortes MA, Weinman J, Horne R (2009) Assessing lay beliefs about generic medicines: Development of the generic medicines scale. Psychol Health Med 14(3):311–321. https://doi.org/10.1080/13548500802613043
MacKrill K, Petrie KJ (2018) What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine? A New Zealand cross-sectional patient survey. BMJ Open 8(10):e023667. https://doi.org/10.1136/bmjopen-2018-023667
Kleinstäuber M, MacKrill K, Petrie KJ (2018) Characteristics of individuals who prefer branded innovator over generic medicines: a New Zealand general population survey. Drugs Therapy Perspect 34(10):478–483. https://doi.org/10.1007/s40267-018-0541-z
Babar ZU, Kan SW, Scahill S (2014) Interventions promoting the acceptance and uptake of generic medicines: A narrative review of the literature. Health Policy 117:285–296. https://doi.org/10.1016/j.healthpol.2014.06.004
Olsson E, Svensberg K, Wallach-Kildemoes H, Carlsson E, Hällkvist C, Kaae S, Kälvemark Sporrong S (2018) Swedish patients’ trust in the bioequivalence of interchangeable generics. What factors are important for low trust? Pharm Pract. https://doi.org/10.18549/PharmPract.2018.04.1298
Alrasheedy AA, Hassali AM, Stewart K, Kong DCM, Aljadhey H, Ibrahim MIM, Al-Tamimi SK (2014) Patient knowledge, perceptions, and acceptance of generic medicines: A comprehensive review of the current literature. Patient Intell 4:1–29. https://doi.org/10.2147/PI.S46737
Faasse K, Grey A, Horne R, Petrie KJ (2015) High perceived sensitivity to medicines is associated with higher medical care utilisation, increased symptom reporting and greater information-seeking about medication. Pharmacoepidemiol Drug Saf 24:592–599. https://doi.org/10.1002/pds.3751
Pechlivanoglou P, van der Veen WJ, Bos JH, Postma MJ (2011) Analyzing generic and branded substitution patterns in the Netherlands using prescription data. BMC Health Serv Res 11:89. https://doi.org/10.1186/1472-6963-11-89
Gasteiger C, Jones ASK, Kleinstäuber M, Lobo M, Horne R, Dalbeth N, Petrie KJ (2019) The effects of message framing on patients’ perceptions and willingness to change to a biosimilar in a hypothetical drug switch. Arthr Care Res. https://doi.org/10.1002/acr.24012(Epub ahead of print)
Broadbent E, Petrie KJ, Main J, Weinman J (2006) The brief illness perception questionnaire. J Psychom Res 60:631–637. https://doi.org/10.1016/j.jpsychores.2005.10.020
Broadbent E, Wilkes C, Koschwanez H, Weinman J, Norton S, Petrie KJ (2015) A systematic review and meta-analysis of the Brief Illness Perception Questionnaire. Psychol Health 30(11):1361–1385. https://doi.org/10.1080/08870446.2015.1070851
Horne R, Weinman J, Hankins M (1999) The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 14:1–24. https://doi.org/10.1080/08870449908407311
Heller MK, Chapman SC, Horne R (2015) Beliefs about medication predict the misattribution of a common symptom as a medication side effect - evidence from an analogue online study. J Psychosom Res 79:519–529. https://doi.org/10.1016/j.jpsychores.2015.10.003
Bautista RE, Gonzales W, Jain D (2011) Factors associated with poor seizure control and increased side effects after switching to generic antiepileptic drugs. Epilepsy Res 95:158–167. https://doi.org/10.1016/j.eplepsyres.2011.03.014
Horne R, Faasse K, Cooper V, Diefenbach MA, Leventhal H, Leventhal E, Petrie KJ (2013) The perceived sensitivity to medicines (PSM) scale: An evaluation of validity and reliability. Br J Health Psychol 18:18–30. https://doi.org/10.1111/j.2044-8287.2012.02071.x
Nolke L, Mensing M, Kramer A, Hornberg C (2015) Sociodemographic and health-(care-)related characteristics of online health information seekers: a cross-sectional German study. BMC Public Health 15:31. https://doi.org/10.1186/s12889-015-1423-0
Dunne S, Shannon B, Dunne C, Cullen W (2014) Patient perceptions of generic medicines: A mixed-methods study. Patient 7:177–185. https://doi.org/10.1007/s40271-013-0042-z
Shaw Y, Metes ID, Michaud K, Donohue JM, Roberts MS, Levesque MC, Chang JC (2018) Rheumatoid arthritis patients’ motivations for accepting or resisting disease-modifying antirheumatic drug treatment regimens. Arthritis Care Res 70(4):533–541. https://doi.org/10.1002/acr.23301
Graham-Engeland JE, Song S, Mathur A, Wagstaff DA, Klein LC, Whetzel C, Ayoub WT (2019) Emotional state can affect inflammatory responses to pain among rheumatoid arthritis patients: preliminary findings. Psychol Rep 122(6):2026–2049. https://doi.org/10.1177/0033294118796655
Dures E, Fraser I, Almeida C, Peterson A, Caesley J, Pollock J, Ambler N, Morris M, Hewlett S (2017) Patients' perspectives on the psychological impact of inflammatory arthritis and meeting the associated support needs: open-ended responses in a multi-centre survey. Musculoskeletal Care 15(3):175–185. https://doi.org/10.1002/msc.1159
McMullan RD, Berle D, Arnáez S, Starcevic V (2019) The relationships between health anxiety, online health information seeking, and cyberchondria: Systematic review and meta-analysis. J Affective Disord 245:270–278. https://doi.org/10.1016/j.jad.2018.11.037
Gasteiger N, Grainger RKD (2018) Arthritis-Related Support in a Social Media Group for Quilting Hobbyists: Qualitative Study. Interact J Med Res 7(2):e11026. https://doi.org/10.2196/11026
Teeple A, Ginsburg S, Howard L, Huff L, Reynolds C, Walls D, Ellis LA, Curtis JR (2019) Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. Curr Med Res Opin 35(4):603–609. https://doi.org/10.1080/03007995.2018.1560221
Edwards CJ, Hercogova J, Albrand H, Amiot A (2019) Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. Expert Opin Biol Ther 19(10):1001–1014. https://doi.org/10.1080/14712598.2019.1610381
Rathe J, Larsen P, Andersen M, Paulsen M, Jarbol D, Thomsen J, Soendergaard J (2013) Associations between generic substitution and patients' attitudes, beliefs and experiences. Eur J Clin Pharmacol 69(10):1827–1836. https://doi.org/10.1007/s00228-013-1539-z
Dunne S (2016) What do users of generic medicines think of them? A systematic review of consumers' and patients' perceptions of, and experiences with, generic medicines. Patient 9:499–510. https://doi.org/10.1007/s40271-016-0176-x
Dunne S, Shannon B, Hannigan A, Dunne C, Cullen W (2014) Physician and pharmacist perceptions of generic medicines: What they think and how they differ. Health Policy 116:214–223. https://doi.org/10.1016/j.healthpol.2014.03.007
Haghnejad V, Le Berre C, Dominique Y, Zallot C, Guillemin F, Peyrin-Biroulet L (2019) Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. Dig Liver Dis. https://doi.org/10.1016/j.dld.2019.09.012
Jacobs I, Singh E, Sewell KL, Al-Sabbagh A, Shane LG (2016) Patient attitudes and understanding about biosimilars: An international cross-sectional survey. Patient Prefer Adher 10:937–948. https://doi.org/10.2147/PPA.S104891
van Overbeeke E, De Beleyr B, de Hoon J, Westhovens R, Huys I (2017) Perception of originator biologics and biosimilars: A survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs 31:447–459. https://doi.org/10.1007/s40259-017-0244-3
Funding
This study was not financially supported by any funding agency or grant.
Author information
Authors and Affiliations
Contributions
CG, KP and ND contributed to the study conception and design, and material preparation. CG, ND and ML contributed to data collection. CG analysed the data. The first draft of the manuscript was written by CG, KP and ND. All authors commented on previous versions of the manuscript and read and approved the final manuscript. All co-authors of the study take full responsibility for the integrity of the final version of the manuscript.
Corresponding author
Ethics declarations
Conflicts of interests
Nicola Dalbeth has received speaker fees, consulting fees, or grants from Janssen and Abbvie, AstraZeneca, and Amgen. The other authors declare no conflicts of interest.
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gasteiger, C., Lobo, M., Dalbeth, N. et al. Patients’ beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch. Rheumatol Int 41, 163–171 (2021). https://doi.org/10.1007/s00296-020-04576-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-020-04576-7